AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24684757 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 450
Study 22867630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 20
Study 22867630 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 20
Study 22867630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 19616195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 62
Study 19616195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 62
Study 17612947 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning cycling exercise at 45 W and 80% of T(vent)
Number of subjects: 14
Study 15558995 — intervention group
Group type: COMPARATOR
Intervention: Control (seated rest for 15 min)
Number of subjects: 7
Study 15558995 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming (cycling ergometry for 15 min at 70% Vo2 peak)
Number of subjects: 7
Study 15558995 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warming (immersion in a circulated bath at 40 degrees C)
Number of subjects: 7
Study 12057066 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (HDI)
Number of subjects: 0
Study 12057066 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 based biochemotherapy
Number of subjects: 0
Study 12057066 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter courses of HDI or vaccines
Number of subjects: 0
Study 12057066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose interferon
Number of subjects: 0
Study 9635714 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of CCNU, vinblastine, procarbazine, and prednisone (CVPP)
Number of subjects: 258
Study 9635714 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of CVPP
Number of subjects: 258
Study 9635714 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of CVPP followed by 25 Gy radiotherapy
Number of subjects: 258
Study 9635714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles CVPP, 25 Gy radiotherapy, and 3 cycles CVPP
Number of subjects: 258
Study 8605053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin prophylaxis
Number of subjects: 1146
Study 2562473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ouabain (doses ranged from 50 micrograms to 5000 micrograms)
Number of subjects: 8
Study 2562473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30500925 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette sampling (weekly supply for 3 weeks)
Number of subjects: 0
Study 30500925 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette sampling
Number of subjects: 0
Study 30500925 — intervention group
Group type: COMPARATOR
Intervention: Control (no e-cigarette sampling)
Number of subjects: 0
Study 30025415 — intervention group
Group type: EXPERIMENTAL
Intervention: NER1006
Number of subjects: 515
Study 30025415 — intervention group
Group type: COMPARATOR
Intervention: SP+MC
Number of subjects: 515
Study 28031390 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 35
Study 28031390 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 35
Study 28031390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24166893 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 2 g
Number of subjects: 92
Study 24166893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU/d
Number of subjects: 92
Study 24166893 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 2 g and Vitamin D3 800 IU/d
Number of subjects: 92
Study 25041370 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Alt-RAMEC/FM protocol
Number of subjects: 31
Study 25041370 — intervention group
Group type: EXPERIMENTAL
Intervention: RME/FM protocol
Number of subjects: 31
Study 25041370 — intervention group
Group type: COMPARATOR
Intervention: Untreated Class III malocclusion (control group)
Number of subjects: 31
Study 21507018 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-group comparative context manipulation in Study 1
Number of subjects: 0
Study 21507018 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-group comparative context manipulation in Study 2
Number of subjects: 0
Study 19361753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine melphalan + alemtuzumab conditioning
Number of subjects: 154
Study 19361753 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine melphalan conditioning (control)
Number of subjects: 154
Study 17710782 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive patients for C. pneumoniae
Number of subjects: 271
Study 17710782 — intervention group
Group type: COMPARATOR
Intervention: Seronegative patients for C. pneumoniae
Number of subjects: 271
Study 15383080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation/perfusion tomography (V/P(SPET))
Number of subjects: 53
Study 15383080 — intervention group
Group type: COMPARATOR
Intervention: Planar lung ventilation/perfusion scintigraphy (V/P(PLANAR))
Number of subjects: 53
Study 11431615 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment with APIS MELLIFICA 9 CH and BRYONIA 9 CH
Number of subjects: 71
Study 11431615 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment comprising naproxen and fluid restriction
Number of subjects: 71
Study 9494026 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed cells without buffy coat (PC)
Number of subjects: 914
Study 9494026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-filtered units (FF)
Number of subjects: 914
Study 9494026 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored-filtered units (SF)
Number of subjects: 914
Study 8039540 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml grapefruit juice taken simultaneously with 10 mg coumarin
Number of subjects: 13
Study 8039540 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml grapefruit juice taken 30 min prior to 10 mg coumarin
Number of subjects: 13
Study 8039540 — intervention group
Group type: EXPERIMENTAL
Intervention: coadministration of grapefruit juice with 10 mg coumarin
Number of subjects: 13
Study 2646997 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.5 mg)
Number of subjects: 102
Study 2646997 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine (5 mg)
Number of subjects: 102
Study 31944318 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative consultation
Number of subjects: 188
Study 31944318 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188
Study 30816640 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously Q6M
Number of subjects: 795
Study 30816640 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg orally QD
Number of subjects: 795
Study 28056435 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat-PGE2
Number of subjects: 245
Study 28056435 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy
Number of subjects: 245
Study 24830710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1144
Study 24830710 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1144
Study 23960051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabrinex supplemented with magnesium sulphate (n=18)
Number of subjects: 36
Study 23960051 — intervention group
Group type: COMPARATOR
Intervention: Pabrinex only (n=18)
Number of subjects: 36
Study 21818722 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 21818722 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (non-invasive low-frequency repetitive transcranial magnetic stimulation)
Number of subjects: 0
Study 21818722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TMS device as placebo)
Number of subjects: 0
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling treatment
Number of subjects: 315
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping treatment
Number of subjects: 315
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 315
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of anosmia
Number of subjects: 315
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of symptoms
Number of subjects: 315
Study 18091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for anosmia
Number of subjects: 315
Study 16127299 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg phytosterols
Number of subjects: 24
Study 16127299 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg phytosterols
Number of subjects: 24
Study 16127299 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg phytosterols
Number of subjects: 24
Study 16127299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11908511 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta2-agonist (salbutamol)
Number of subjects: 134
Study 11908511 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta2-agonist (formoterol)
Number of subjects: 134
Study 11908511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10452629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg per week
Number of subjects: 323
Study 10452629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 7606068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-L WBI at 2 L/h
Number of subjects: 9
Study 7606068 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-L WBI at 2 L/h
Number of subjects: 9
Study 2218650 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 20.4 g of psyllium daily
Number of subjects: 59
Study 2218650 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 59
Study 319322 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandrostenolone
Number of subjects: 26
Study 319322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 29493059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 188
Study 29493059 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 188
Study 27288389 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing interest statements in Clinical Reviews
Number of subjects: 2040
Study 24976452 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding breastfeeding before and after vaccination
Number of subjects: 400
Study 24976452 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding half an hour before and after vaccination
Number of subjects: 400
Study 22127230 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 7
Study 22127230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 7
Study 21114174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level nitrogen laser therapy along with antitubercular treatment (ATT)
Number of subjects: 104
Study 21114174 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ATT only)
Number of subjects: 104
Study 19281914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment >12 hours before coronary stenting
Number of subjects: 0
Study 19281914 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose, 10 mg/d maintenance dose)
Number of subjects: 0
Study 19281914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose administered at least 15 hours before elective PCI
Number of subjects: 0
Study 19281914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment before diagnostic catheterization
Number of subjects: 0
Study 19281914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg pretreatment before elective PCI
Number of subjects: 0
Study 15954913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 687
Study 15954913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 15954913 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CRP level
Number of subjects: 687
Study 15954913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertile of sTNFrii
Number of subjects: 687
Study 12585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 12585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplements (vitamins E and C)
Number of subjects: 0
Study 10636510 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 150 mg/day)
Number of subjects: 415
Study 10636510 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/day)
Number of subjects: 415
Study 10636510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 10636510 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (combined groups)
Number of subjects: 415
Study 10636510 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 415
Study 8592021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 8592021 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials and counseling
Number of subjects: 0
Study 1549991 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 84
Study 3923180 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 260
Study 3923180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 260
Study 3923180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 30132393 — intervention group
Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'better'
Number of subjects: 1017
Study 30132393 — intervention group
Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'more' (better for function, worse for symptoms)
Number of subjects: 1017
Study 30132393 — intervention group
Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'normed' to a population average
Number of subjects: 1017
Study 27586249 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg for 4 weeks
Number of subjects: 62
Study 27586249 — intervention group
Group type: COMPARATOR
Intervention: placebo for 4 weeks
Number of subjects: 62
Study 25187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Left vagus nerve stimulation (VNS)
Number of subjects: 60
Study 25187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Right vagus nerve stimulation (VNS)
Number of subjects: 60
Study 25187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined population (both left and right VNS)
Number of subjects: 60
Study 25187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side ART
Number of subjects: 60
Study 22916819 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meal (lentil-based, GI about 42)
Number of subjects: 14
Study 22916819 — intervention group
Group type: COMPARATOR
Intervention: High-GI meal (potato-based, GI about 78)
Number of subjects: 14
Study 19858315 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 42
Study 19858315 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH stimulation
Number of subjects: 42
Study 19858315 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 stimulation
Number of subjects: 42
Study 19858315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17922458 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMA‐IgM ELISA
Number of subjects: 0
Study 17922458 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMA‐IgG ELISA
Number of subjects: 0
Study 15801940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramolecular homeopathic medicines in C-30 potency administered twice weekly for 12 weeks
Number of subjects: 251
Study 15801940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 12145064 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 72
Study 12145064 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg of midazolam IV
Number of subjects: 72
Study 12145064 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/kg of midazolam IV
Number of subjects: 72
Study 10610626 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program 'Thriving in a Busy Practice: Physician‐Patient Communication' consisting of two 4‐hour interactive workshops
Number of subjects: 69
Study 10610626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no communication skills training)
Number of subjects: 69
Study 8916472 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal ring
Number of subjects: 0
Study 8916472 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second estradiol vaginal ring
Number of subjects: 0
Study 1379969 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran (loading dose of 1,000 anti‐Xa units intravenously followed by 750 anti‐Xa units subcutaneously 12‐hourly)
Number of subjects: 162
Study 1379969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 1379969 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran (750 anti‐factor Xa units subcutaneously 12‐hourly)
Number of subjects: 162
Study 1379969 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units subcutaneously 12‐hourly)
Number of subjects: 162
Study 6387208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0
Study 6387208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31701607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient sleep (4 hours per night)
Number of subjects: 22
Study 31701607 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (7-8 hours per night)
Number of subjects: 22
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sample (2113 patients)
Number of subjects: 4227
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Test sample (1057 patients)
Number of subjects: 4227
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation sample (1057 patients)
Number of subjects: 4227
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model (C statistics)
Number of subjects: 4227
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class model (C statistic)
Number of subjects: 4227
Study 30646102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 4227
Study 26554661 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 1 year
Number of subjects: 165
Study 26554661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 23443441 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily (n=213)
Number of subjects: 422
Study 23443441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=209)
Number of subjects: 422
Study 23443441 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 422
Study 21595575 — intervention group
Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi decoction (DCQD) administered for 7 days
Number of subjects: 70
Study 21595575 — intervention group
Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi decoction (DCQD) in SAP rat models
Number of subjects: 70
Study 19556579 — intervention group
Group type: EXPERIMENTAL
Intervention: Free soap and handwashing promotion for 9 months
Number of subjects: 0
Study 19556579 — intervention group
Group type: EXPERIMENTAL
Intervention: Former intervention households
Number of subjects: 0
Study 16705588 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-based treatment
Number of subjects: 355
Study 16705588 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based treatment
Number of subjects: 355
Study 16705588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 355
Study 15271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-activated cardioversion with sedation
Number of subjects: 15
Study 15271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic night cardioversion with sedation
Number of subjects: 15
Study 15271009 — intervention group
Group type: COMPARATOR
Intervention: Automatic night cardioversion without sedation
Number of subjects: 15
Study 11747870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive preparations (three different marketed OC preparations)
Number of subjects: 818
Study 11747870 — intervention group
Group type: COMPARATOR
Intervention: Previous OC users (switchers)
Number of subjects: 818
Study 11747870 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal birth control methods (starters)
Number of subjects: 818
Study 11747870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive preparations (during treatment)
Number of subjects: 818
Study 11747870 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory screening for APC-resistance using Coatest APC, ProC Global, or ProC APC-FV-Leiden
Number of subjects: 818
Study 9242856 — intervention group
Group type: EXPERIMENTAL
Intervention: Added-purpose occupation
Number of subjects: 20
Study 9242856 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise condition
Number of subjects: 20
Study 8295815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension, 7.5 mg/kg twice daily
Number of subjects: 506
Study 8295815 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK suspension, 13.3 mg/kg three times per day
Number of subjects: 506
Study 8295815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 506
Study 8295815 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 506
Study 2830588 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin
Number of subjects: 60
Study 2830588 — intervention group
Group type: COMPARATOR
Intervention: Control (no CMV immunoglobulin)
Number of subjects: 60